表皮生长因子受体与c-erbB-2共表达对局部晚期宫颈癌的不良预后影响

Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer.

作者信息

Pérez-Regadera José, Sánchez-Muñoz Alfonso, De-la-Cruz Javier, Ballestín Claudio, Lora David, García-Martín Rosa, Mendiola Cesar, Alonso Lorenzo, Alba Emilio, Lanzós Eduardo

机构信息

Department of Radiation Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain.

出版信息

Oncology. 2009;76(2):133-41. doi: 10.1159/000195539. Epub 2009 Jan 28.

DOI:10.1159/000195539

PMID:19174612

Abstract

OBJECTIVE

The objective was to determine the impact of the coexpression of epidermal growth factor receptor (EGFR) and tumor marker c-erbB-2 on disease-free survival (DFS) and pelvic relapse-free survival (PRFS) in patients with locally advanced cervical cancer (LACC) receiving concurrent chemoradiotherapy.

METHODS

The expression of EGFR and c-erbB-2 was assessed by immunohistochemistry, which was centralized and blinded to outcome. Univariate and multivariate analyses were used to evaluate the impact of EGFR and c-erbB-2 on DFS and PRFS.

RESULTS

170 patients with LACC were included and received concurrent chemoradiotherapy. 25 (15%) biopsies were considered EGFR and c-erbB-2 positive; 100 (59%) were either EGFR or c-erbB-2 positive, and 45 (26%) were EGFR and c-erbB-2 negative. The 3- and 5-year DFS was 39% each for EGFR- and c-erbB-2-positive patients, 54 and 49%, respectively, for EGFR- or c-erbB-2-positive patients, and 76 and 72%, respectively, for EGFR- and c-erbB-2-negative patients (p = 0.006). EGFR- and c-erbB-2-positive tumors were significantly associated with a decrease in PRFS (hazard ratio, HR, 3.99; 95% confidence interval, CI, 1.44-11.05, p = 0.007), and DFS (HR 2.9; 95% CI, 1.26-6.66, p = 0.01).

CONCLUSION

Patients with LACC coexpressing EGFR and c-erbB-2, and treated with concurrent chemoradiotherapy, had a worse clinical prognosis with shorter DFS and PRFS.

摘要

目的

确定表皮生长因子受体（EGFR）与肿瘤标志物c-erbB-2共表达对接受同步放化疗的局部晚期宫颈癌（LACC）患者无病生存期（DFS）和盆腔无复发生存期（PRFS）的影响。

方法

采用免疫组织化学法评估EGFR和c-erbB-2的表达，评估过程集中进行且对结果设盲。采用单因素和多因素分析评估EGFR和c-erbB-2对DFS和PRFS的影响。

结果

纳入170例LACC患者并接受同步放化疗。25份（15%）活检标本被认为EGFR和c-erbB-2呈阳性；100份（59%）为EGFR或c-erbB-2呈阳性，45份（26%）为EGFR和c-erbB-2呈阴性。EGFR和c-erbB-2阳性患者的3年和5年DFS均为39%，EGFR或c-erbB-2阳性患者分别为54%和49%，EGFR和c-erbB-2阴性患者分别为76%和72%（p = 0.006）。EGFR和c-erbB-2阳性肿瘤与PRFS降低显著相关（风险比，HR，3.99；95%置信区间，CI，1.44 - 11.05，p = 0.007），与DFS降低也显著相关（HR 2.9；95% CI，1.26 - 6.66，p = 0.01）。